Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › VolitionRx Plans Partnership to Launch Cancer Dx Platform in China

VolitionRx Plans Partnership to Launch Cancer Dx Platform in China

Mar 28, 2019
|
staff reporter

NEW YORK (360Dx) — Belgian diagnostics firm VolitionRx announced today that it is planning a partnership with Shanghai Fosun Long March Medical Science to introduce its NuQ blood-based cancer diagnostic platform in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Cancer

  1. Foundation Medicine Shifts Focus to Early Cancer Detection With Lexent Bio Acquisition

    Premium

  2. OncoCyte Downgraded to Neutral by Piper Sandler on Unsuccessful Results for Lung Cancer Test

  3. AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection

    Premium

  4. Bladder Cancer Test From KDx Diagnostics Gets CE Mark

  5. Oncotype DX Predicts Outcomes in Men With Unfavorable Intermediate-Risk Prostate Cancer, Study Finds

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.